Skip to main content
Shanghai Haohai Biological Technology Co., Ltd. logo

Shanghai Haohai Biological Technology Co., Ltd. — Investor Relations & Filings

Ticker · 6826 ISIN · CNE100001W69 LEI · 5299005V6H42CRB17Z16 HKEX Manufacturing
Open in API
Filings indexed 1,485 across all filing types
Latest filing 2026-05-29 Board/Management Inform…
Country CN China
Listing HKEX 6826

About Shanghai Haohai Biological Technology Co., Ltd.

http://www.3healthcare.com

Shanghai Haohai Biological Technology Co., Ltd. is a leading biomedical enterprise focused on the research, development, manufacturing, and commercialization of absorbable medical biological materials, medical devices, and pharmaceutical products. The company strategically targets high-growth therapeutic fields, including Ophthalmology, Medical Aesthetics and Wound Care, Orthopedics, Anti-adhesion, and Hemostasis. Haohai is a major supplier in the Chinese artificial intraocular lens (IOL) market and is recognized globally as an independent ophthalmic material manufacturer. Its core mission involves developing innovative healthcare solutions, primarily serving the Chinese market while maintaining a presence in Europe and other international regions.

Recent filings

Filing Released Lang Actions
上海昊海生物科技股份有限公司关于董事长兼核心技术人员离任暨选举董事长、变更法定代表人、增补专门委员会成员的公告
Board/Management Information Classification · 92% confidence The document is an announcement by Shanghai Haohai Biotechnology Co., Ltd. regarding the resignation of its chairman and core technical personnel, the election of a new chairman, change of the legal representative, and additions to board committees. It details board-level changes and committee compositions, matching the definition of a Board/Management Information filing. It is not a report publication notice or financial report but an actual management change announcement.
2026-05-29 Chinese
上海昊海生物科技股份有限公司2025年年度股东会、2026年第一次A股类别股东会及2026年第一次H股类别股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions and voting results from the 2025 annual general meeting and the 2026 first A-share and H-share class meetings, detailing vote counts and percentages for each agenda. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-05-29 Chinese
H股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is an FF305 “Next Day Disclosure” form under the HKEx Main Board/GEM listing rules (13.25A/17.27A) detailing changes in issued shares and treasury stock, including a section on share buybacks and repurchase report. It is not a manager presentation or financial statement, but a regulatory announcement of the company’s own share transactions (repurchases). This matches the category “Transaction in Own Shares (POS).”
2026-05-13 Chinese
H股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a Hong Kong Exchange “翌日披露報表” (Form FF305) disclosing share capital movements, including detailed repurchases of the company’s own H-shares and A-shares under HKEX Main Board / GEM Listing Rules 13.25A/17.27A etc. It is a mandated regulatory disclosure of share buybacks and treasury share transactions. This exactly matches our “Transaction in Own Shares” category (POS).
2026-05-12 Chinese
H股公告：翌日披露报表
Transaction in Own Shares Classification · 85% confidence The document is an HKEX FF305 “Next Day Disclosure Form” outlining changes in issued shares and treasury shares, including detailed share repurchases (dates, quantities, prices) and treasury share transactions under the Main Board/GEM Listing Rules. This is not an earnings release, annual report, or general regulatory announcement but a specific share buy‐back/own share transaction report. Therefore, it best fits the “Transaction in Own Shares” category (POS).
2026-05-11 Chinese
H股公告：翌日披露报表
Transaction in Own Shares Classification · 95% confidence The document is a detailed disclosure report about changes in issued shares, treasury shares, and share repurchases by Shanghai Haohai Biological Technology Co., Ltd. It references specific Hong Kong Stock Exchange Listing Rules (Main Board and GEM) sections 13.25A, 17.27A, 10.06(4)(a), and others, which govern disclosures related to share issuance, repurchases, and treasury shares. The document includes detailed tables of share counts, repurchase dates, prices, and confirmations of compliance with listing rules. It is not a financial report like an annual or interim report, nor is it a management or earnings discussion. It is a regulatory disclosure specifically about share repurchases and changes in share capital. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length (6168 characters) and content confirm it is the actual disclosure report, not just an announcement or certification. Therefore, the correct classification is POS with high confidence.
2026-05-08 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.